secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2025-05-02T23:59:59+00:00
Accession:  0001689548-25-000056
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis posts Q1 net loss of $69.3M; cash $472M, runway into 2028
----------------------------------------------------------------

- Net loss $69.3M for Q1 2025 vs $39.6M YoY; R&D spend $60.8M (up 125% YoY).
- Cash & investments $472M as of March 31, 2025; no revenue recognized.
- Essential3 essential tremor trial continues after futility interim; topline Q3 2025.
- Vormatrigine RADIANT topline mid-2025, POWER1 H2 2025; EMERALD & EMBRAVE3 studies to start mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000056/0001689548-25-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000056/prax-20250502.htm
  HTML page:      https://secwatch.observer/filing/0001689548-25-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer